RANDOMIZED STUDY OF DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH OR WITHOUT INTERMITTENT SUNITINIB IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WITH MEASURABLE PRIMARY BREAST TUMOR: